Cell therapies are already here, with treatments now available for some cancers and rare diseases. But bringing such living medicines to more patients presents both scientific and financial challenges ...
CHICAGO--(BUSINESS WIRE)--Syntax Bio, a preclinical-stage biotechnology company, has launched with backing from Astellas Venture Management LLC and Illumina Ventures. Other investors include DCVCBio, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback